|
PIGO expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.29099994530912E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.12379999645174E-08 |
| Normal-vs-Stage2 |
8.681500E-03 |
| Normal-vs-Stage3 |
8.4509954589862E-11 |
| Normal-vs-Stage4 |
3.56539999968319E-07 |
| Stage1-vs-Stage2 |
7.983900E-02 |
| Stage1-vs-Stage3 |
6.899700E-02 |
| Stage1-vs-Stage4 |
5.056600E-01 |
| Stage2-vs-Stage3 |
9.995900E-03 |
| Stage2-vs-Stage4 |
6.420400E-02 |
| Stage3-vs-Stage4 |
4.942800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.38620020912117E-10 |
| Normal-vs-AfricanAmerican |
4.630400E-04 |
| Normal-vs-Asian |
3.09980000001708E-06 |
| Caucasian-vs-AfricanAmerican |
5.787000E-01 |
| Caucasian-vs-Asian |
6.543400E-01 |
| AfricanAmerican-vs-Asian |
8.339800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.3769000080427E-09 |
| Normal-vs-Female |
1.53689999615736E-08 |
| Male-vs-Female |
1.998790E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.29040000299108E-08 |
| Normal-vs-Age(41-60Yrs) |
4.02069999516641E-08 |
| Normal-vs-Age(61-80Yrs) |
3.61280000027442E-07 |
| Normal-vs-Age(81-100Yrs) |
1.001770E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.770600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.161000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.241000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.008800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.490600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.396800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.574600E-04 |
| Classical-VS-Follicular |
6.017800E-02 |
| Classical-VS-Other |
7.778400E-02 |
| Classical-VS-Normal |
3.09209990945192E-10 |
| Tall-VS-Follicular |
4.4865000000005E-05 |
| Tall-VS-Other |
6.684600E-01 |
| Tall-VS-Normal |
3.9984682231875E-12 |
| Follicular-VS-Other |
7.490000E-02 |
| Follicular-VS-Normal |
2.344200E-03 |
| Other-VS-Normal |
6.01129999999728E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.4515999997905E-07 |
| Normal-vs-N1 |
1.51430001871233E-09 |
| N0-vs-N1 |
8.879000E-03 |
|
|
